Elanco Animal Health
$ 26.19
-2.42%
26 Feb - close price
- Market Cap 13,335,816,000 USD
- Current Price $ 26.19
- High / Low $ 26.93 / 26.11
- Stock P/E 383.43
- Book Value 13.17
- EPS 0.07
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE -0.04 %
- 52 Week High 27.72
- 52 Week Low 8.02
About
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures and markets products for pets and farm animals. The company is headquartered in Greenfield, Indiana.
Analyst Target Price
$27.62
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-11-05 | 2025-08-07 | 2025-05-06 | 2025-02-24 | 2024-11-07 | 2024-08-08 | 2024-05-08 | 2024-02-26 | 2023-11-07 | 2023-08-07 | 2023-05-09 |
| Reported EPS | 0.13 | 0.19 | 0.26 | 0.37 | 0.14 | 0.13 | 0.3 | 0.34 | 0.08 | 0.18 | 0.18 | 0.45 |
| Estimated EPS | 0.1135 | 0.13 | 0.2 | 0.3044 | 0.1486 | 0.12 | 0.24 | 0.26 | 0.11 | 0.12 | 0.05 | 0.29 |
| Surprise | 0.0165 | 0.06 | 0.06 | 0.0656 | -0.0086 | 0.01 | 0.06 | 0.08 | -0.03 | 0.06 | 0.13 | 0.16 |
| Surprise Percentage | 14.5374% | 46.1538% | 30% | 21.5506% | -5.7873% | 8.3333% | 25% | 30.7692% | -27.2727% | 50% | 260% | 55.1724% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.3522 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ELAN
2026-02-25 15:37:41
Keybanc has increased its price target for Elanco Animal Health (ELAN) from $27.00 to $29.00, reiterating an Overweight rating. This decision follows a series of positive analyst revisions, with Leerink Partners, JP Morgan, and Piper Sandler also raising their price targets and/or upgrading their ratings for ELAN in recent months. Despite the positive analyst sentiment and an average target price implying a slight upside, GuruFocus estimates suggest a significant downside in the stock's fair value.
2026-02-25 13:52:41
Elanco Animal Health (NYSE:ELAN) reported strong Q4 2025 financial results, with organic constant currency revenue growth of 9%, exceeding guidance for revenue, adjusted EBITDA, and adjusted EPS. The company highlighted significant contributions from innovation, particularly Credelio Quattro and Zenrelia, and faster-than-anticipated deleveraging. Elanco also provided robust 2026 guidance, projecting 4% to 6% organic constant currency revenue growth and an 8% increase in adjusted EBITDA at the midpoint, emphasizing its strategic focus on growth, innovation, and cash generation in a dynamic animal health market.
2026-02-24 15:52:41
Elanco Animal Health Inc. has released its 2025 10-K report, detailing a 6% revenue increase to $4,715 million but a net loss of $(232) million due to restructuring charges. The report highlights strategic initiatives like a restructuring plan and divestiture of its aqua business, alongside new product launches and expanded manufacturing. The company faces significant challenges from market competition, regulatory changes, and substantial indebtedness, which management plans to address through R&D, acquisitions, and debt management.
2026-02-24 15:52:41
Elanco Animal Health announced its financial results for Q4 and full year 2025, reporting increased revenue and progress in strategic priorities. The company highlighted key milestones including product approvals and market share gains for several products. Elanco also provided initial guidance for 2026, forecasting continued growth, improved adjusted EBITDA, and a reduction in its net leverage ratio.
2026-02-24 15:52:41
Elanco Animal Health (ELAN) has seen a significant 122.8% increase in its share price over the last year. Despite this jump, a Discounted Cash Flow (DCF) analysis by Simply Wall St suggests the stock is currently undervalued by approximately 30.9%, with an estimated intrinsic value of $35.81 per share compared to its recent price of $24.75. The article also explores various investor "narratives," including bull and bear cases, to help assess the stock's future potential.
2026-02-24 06:49:00
Elanco Animal Health (ELAN) reported a significantly wider net loss of $276 million in Q4, compared to an $8 million loss in the prior-year quarter, despite a 12% increase in total revenues to $1.14 billion. The company projects adjusted earnings for Q1 2026 to be between $0.33 and $0.36 per share, with revenues between $1.280 billion and $1.305 billion. For the full fiscal year 2026, Elanco anticipates adjusted earnings in the range of $1.00 to $1.06 per share on revenues of $4.95 billion to $5.02 billion, with organic constant currency revenue growth of 4 to 6 percent.
